Parkside Financial Bank & Trust lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 8.1% in the second quarter, Holdings Channel reports. The institutional investor owned 38,358 shares of the biopharmaceutical company’s stock after buying an additional 2,866 shares during the quarter. Pfizer accounts for approximately 0.6% of Parkside Financial Bank & Trust’s portfolio, making the stock its 29th biggest position. Parkside Financial Bank & Trust’s holdings in Pfizer were worth $2,011,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also made changes to their positions in the company. Piscataqua Savings Bank grew its holdings in shares of Pfizer by 0.8% during the second quarter. Piscataqua Savings Bank now owns 25,820 shares of the biopharmaceutical company’s stock worth $1,354,000 after purchasing an additional 197 shares during the last quarter. Birinyi Associates Inc. grew its holdings in shares of Pfizer by 3.4% during the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 200 shares during the last quarter. Curbstone Financial Management Corp grew its holdings in shares of Pfizer by 0.3% during the first quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company’s stock worth $3,412,000 after purchasing an additional 200 shares during the last quarter. Douglass Winthrop Advisors LLC lifted its stake in shares of Pfizer by 0.3% during the first quarter. Douglass Winthrop Advisors LLC now owns 57,804 shares of the biopharmaceutical company’s stock valued at $2,993,000 after acquiring an additional 200 shares during the period. Finally, Oak Harbor Wealth Partners LLC lifted its stake in shares of Pfizer by 0.3% during the first quarter. Oak Harbor Wealth Partners LLC now owns 70,464 shares of the biopharmaceutical company’s stock valued at $3,648,000 after acquiring an additional 203 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.
Pfizer Trading Up 1.5 %
NYSE PFE opened at $44.57 on Friday. The firm has a market cap of $250.14 billion, a P/E ratio of 8.72, a P/E/G ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. The stock’s 50-day moving average is $48.40 and its 200-day moving average is $50.33. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s payout ratio is presently 31.31%.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on PFE. UBS Group set a $59.00 price target on Pfizer in a research note on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, June 28th. Morgan Stanley cut their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research note on Friday, July 8th. SVB Leerink cut their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. Finally, Barclays set a $50.00 target price on Pfizer in a research note on Thursday, September 1st. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.00.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.